Key result
Cotransplanting mesenchymal stem cells and macrophages reduces cardiac fibrosis ~20% versus stem cells alone.
Why the study?
The interaction between bone marrow-derived mesenchymal stem cells and macrophages and their combined therapeutic efficacy in cardiac repair after myocardial infarction was unclear.
Does a mixture of BMMSCs and BMDMs improve cardiac repair compared to BMMSCs alone in rats with induced myocardial infarction?
Does a mixture of BMMSCs and BMDMs improve cardiac repair compared to BMMSCs alone in rats with induced myocardial infarction?
Absolute Event Rate: 15.9% vs 19.8%
Priming macrophages with bone marrow-derived mesenchymal stem cells enhances their therapeutic efficacy for cardiac repair following myocardial infarction in a rat model.
May support combined cell therapy in rodent MI models; hypothesis-generating with no clinical implications yet.
Bone marrow-derived mesenchymal stem cells (BMMSCs) are used extensively for cardiac repair and interact with immune cells in the damaged heart. Macrophages are known to be modulated by stem cells, and we hypothesized that priming macrophages with BMMSCs would enhance their therapeutic efficacy. Rat bone marrow-derived macrophages (BMDMs) were stimulated by lipopolysaccharide (LPS) with or without coculture with rat BMCs. In the LPS-stimulated BMDMs, induction of the inflammatory marker iNOS was attenuated, and the anti-inflammatory marker Arg1 was markedly upregulated by coculture with BMMSCs. Myocardial infarction (MI) was induced in rats. One group was injected with BMMSCs, and a second group was injected with MIX (a mixture of BMMSCs and BMDMs after coculture). The reduction in cardiac fibrosis was greater in the MIX group than in the BMC group. Cardiac function was improved in the BMMSC group and was substantially improved in the MIX group. Angiogenesis was better in the MIX group, and anti-inflammatory macrophages were more abundant in the MIX group than in the BMMSC group. In the BMMSCs, interferon regulatory factor 5 (IRF5) was exclusively induced by coculture with macrophages. IRF5 knockdown in BMMSCs failed to suppress inflammatory marker induction in the macrophages. In this study, we demonstrated the successful application of BMDMs primed with BMMSCs as an adjuvant to cell therapy for cardiac repair. A tailored technique involving stem cells and anti-inflammatory immune cells shows promise for repairing heart tissue damage. Immune cells called anti-inflammatory macrophages are vital for healing of the heart following a heart attack. Youngkeun Ahn, Yong Sook Kim and co-workers at Chonnam National University Hospital in Gwangju, South Korea trialed a novel stem cell therapy on rats to improve cardiac repair. They took bone marrow-derived macrophages and stem cells from each rat and incubated the two cell types together to create individualized treatments. Following induced heart attacks, they injected one group of rats with both cell types, and another group with stem cells only. While heart function improved in both groups, the group treated with both cell types showed significant improvements with a greater reduction in cardiac fibrosis and increased the reparative activity of macrophages.
No takes yet. Share an insight, caveat, or question.
Lim et al. (2018) studied Myocardial infarction (n=27). Mixture of BMMSCs and BMDMs (MIX) vs. BMMSCs alone or PBS was evaluated on Cardiac fibrosis. Cotransplantation of bone marrow-derived mesenchymal stem cells and macrophages into the infarcted myocardium reduced cardiac fibrosis to 15.9% compared to 19.8% with stem cells alone.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: